RATIONALE: ''Sulfa'' antibiotic allergy is commonly reported and often leads to avoidance of both sulfonamide antibiotics and non-cross-reactive non-antibiotic sulfonamides. Evidence-based testing strategies for sulfa allergy labels are lacking. METHODS: We examined the outcomes of oral challenge to trimethoprim-sulfamethoxazole (TMP-SMX) in 157 consecutive patients referred as ''sulfa'' allergic to a drug allergy clinic. Patients with severe cutaneous adverse drug reactions or organ failure were excluded. Graded (40/8 mg;400/80 mg) was used for patients with histories of immediate reactions within the last 5 years, and single dose 400/80 mg for all others. A followup survey and chart review were used to determine subsequent tolerance. RESULTS: Of 157 patients, 131 were immunocompetent, 17 were non-HIV immunocompromised and 9 were HIV-infected. 148/157 (94.3%) tolerated oral challenge; 129/134 of single dose and 19/23 of graded oral challenges. There were no serious reactions. Significantly less time had elapsed since original reaction in patients who failed oral challenge (mean 6.5 years, 95% CI 1.4, 11.5) versus passed (23.4 years, 95% CI 20.4, 26.4), p<0.005. In multivariable logistic regression adjusted for age, sex, and race, increasing time since reaction also protected against challenge failure, aOR 0.84 (95% CI 0.72, 0.97), p50.02. 23/148 (15.5%) challenge negative patients underwent > _ 1 subsequent treatment with TMP-SMX, 20 (87%) uneventfully, 2 with mild delayed-onset rash, and 1 with a nonallergic side effect. CONCLUSIONS: Single and graded oral challenge with TMP-SMX is a safe and effective strategy to remove suspected sulfa antibiotic allergy labels and allow future treatment in patients with non-serious and remote reactions.
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Investigation into the a-Gal syndrome: Characteristics of a large cohort sensitized to galactose-a-1,3-galactose (a-Gal) RATIONALE: Galactose-a-1,3-galactose (a-Gal) is an oligosaccharide that is causal in a syndrome of IgE-mediated delayed anaphylaxis to mammalian meat. Here we describe clinic and serologic features of a large cohort of children and adults who reported histories of urticaria or anaphylaxis to mammalian meat. METHODS: This observational study consisted of 408 subjects. Most reported episodes of anaphylaxis or urticaria, often relating to mammalian meat; 36 were enrolled as asymptomatic controls. Subjects had blood drawn for serologic assays and completed a detailed questionnaire. RESULTS: Of the cohort, specific IgE (sIgE) to a-Gal > _0.35 IU/mL was detected in 311. Of these, 212 were considered 'classic' a-Gal syndrome on the basis of histories of reactions to mammalian meat with onset > _ 2hrs after ingestion. These classic cases were mostly adults (82%) with a mean age of symptom onset of 42 years. Titers of sIgE to a-Gal were similar regardless of inhalant sensitization status and were not associated with reaction severity, but were higher in subjects with a-Gal syndrome than sensitized subjects who were asymptomatic. B-antigen blood group was under-represented in subjects with classic a-Gal syndrome, however amongst the classic cases subjects with the B-antigen had higher relative titers of a-Gal sIgE than subjects without B antigen. CONCLUSIONS: The a-Gal syndrome represents a food allergy to an oligosaccharide present in non-primate mammals as glycoproteins and glycolipids and has several distinguishing features. The syndrome occurs commonly in subjects without traditional atopy, has a characteristic delay in symptom onset and is affected by ABO status.
